Treatment of grade 3 anal intraepithelial neoplasia by complete anal mucosal excision without fecal diversion

1999 ◽  
Vol 42 (10) ◽  
pp. 1342-1344 ◽  
Author(s):  
Marie Lyons ◽  
Nicholas Francis ◽  
Timothy G. Allen-Mersh
Keyword(s):  
Intraepithelial Neoplasia ◽  
Fecal Diversion ◽  
Anal Intraepithelial Neoplasia ◽  
Grade 3

Photodynamic therapy with systemic meta-tetrahydroxyphenylchlorin in the treatment of anal intraepithelial neoplasia, grade 3

2012 ◽  
Vol 44 (8) ◽  
pp. 637-644 ◽  
Author(s):  
Eric M. van der Snoek ◽  
Jan C. den Hollander ◽  
Jan B. Aans ◽  
Henricus J.C.M. Sterenborg ◽  
Marchina E. van der Ende ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Intraepithelial Neoplasia ◽  
Anal Intraepithelial Neoplasia ◽  
Grade 3

Grade 3 Anal Intraepithelial Neoplasia in an HIV-Infected African Girl

2013 ◽  
pp. 1 ◽  
Author(s):  
Marco Zaramella ◽  
Gian Battista Parigi ◽  
Renato Rosso ◽  
Anna Maccabruni
Keyword(s):  
Intraepithelial Neoplasia ◽  
Anal Intraepithelial Neoplasia ◽  
Grade 3

scholarly journals Multicentre Evaluation of Hepika Test Clinical Accuracy in Diagnosing HPV-Induced Cancer and Precancerous Lesions of the Uterine Cervix

Diagnostics ◽  
2021 ◽  
Vol 11 (4) ◽  
pp. 619
Author(s):  
Daniela Gustinucci ◽  
Lucia Ciccocioppo ◽  
Luigi Coppola ◽  
Giovanni Negri ◽  
Gianfranco Zannoni ◽  
...  
Keyword(s):  
Uterine Cervix ◽  
Protein Complexes ◽  
Precancerous Lesions ◽  
Intraepithelial Neoplasia ◽  
Population Based ◽  
Enzyme Linked Immunosorbent Assay ◽  
Lower Sensitivity ◽  
Adenocarcinoma In Situ ◽  
Clinical Accuracy ◽  
Grade 3

Objective: To evaluate the clinical accuracy of Hepika test to identify cancer/precancerous lesions of the uterine cervix. Materials and Methods: A multicentre retrospective study was carried out in 2018 and included 330 liquid-based cytology samples from three Italian centres of women aged 25–64 who had been tested for the human papillomavirus (HPV) and whose histology or follow-up outcome was known. Hepika is an enzyme-linked immunosorbent assay (ELISA) targeting the protein complexes E6#p53 and E7#pRb. After excluding samples without sufficient residual material, the clinical accuracy of Hepika test was evaluated in 274 samples: adenocarcinoma (ADC) (4), squamous cell carcinoma (SCC) (7), adenocarcinoma in situ (AIS) (1), cervical intraepithelial neoplasia (CIN) grade 3 (60), CIN2 (51), CIN1 (34), and negative histology (117). Association, sensitivity, and specificity for carcinoma, CIN3+ and CIN2+ are reported. Results: Positive Hepika test was associated with a high probability of carcinoma (odds ratio (DOR) = 33.68, 95% confidence interval (CI) 7.0–163.1); sensitivity was 81.8%, specificity, 88.2%. A positive Hepika test showed a weaker association with CIN3+ lesions (DOR = 3.5; 95% CI 1.75–6.99) and lower sensitivity (27.8%). Conclusion: The Hepika test was found to be an accurate biomarker for HPV-induced cervical carcinoma. Population-based prospective studies are needed to confirm the clinical usefulness of the Hepika test in the differential diagnosis of HPV-induced invasive lesions.

Sign in / Sign up

Export Citation Format

Share Document